We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Rydapt

News List

FAQs About Rydapt (Midostaurin): Understanding Its Uses and Benefits PharmaSources
November 17, 2023
The recent approval of Rydapt (Midostaurin) by the FDA has generated a lot of interest and questions regarding this new targeted therapy for acute myeloid leukemia (AML) and aggressive systemic mastocytosis (ASM).
Astellas’ Xospata wins FDA nod in AML, with Daiichi competition looming fiercepharma
December 06, 2018
On an acute myeloid leukemia (AML) roll, the FDA has green-lighted Astellas’ Xospata, also known as gilteritinib. For Astellas, it marks the first step toward challenging Novartis’ Rydapt and likely just a slim head start against Daiichi Sankyo.